{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:37:12Z","timestamp":1776778632315,"version":"3.51.2"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.lana.2023.100506","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T06:41:50Z","timestamp":1684305710000},"page":"100506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-5910","authenticated-orcid":false,"given":"Adriana M.","family":"Ivama-Brummell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-3822","authenticated-orcid":false,"given":"Fernanda L.","family":"Marciniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-6668","authenticated-orcid":false,"given":"Anita K.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-7216","authenticated-orcid":false,"given":"Claudia G.S.","family":"Osorio-de-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-4397","authenticated-orcid":false,"given":"Sabine","family":"Vogler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8664-9297","authenticated-orcid":false,"given":"Elias","family":"Mossialos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-0917","authenticated-orcid":false,"given":"Carla L.","family":"Tavares-de-Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-5751","authenticated-orcid":false,"given":"Huseyin","family":"Naci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2023.100506_bib1","series-title":"Global oncology trends 2022","first-page":"65","year":"2022"},{"key":"10.1016\/j.lana.2023.100506_bib2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(19)33178-2","article-title":"Generating comparative evidence on new drugs and devices before approval","volume":"395","author":"Naci","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lana.2023.100506_bib3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.lana.2023.100506_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jnci\/djx232","article-title":"Magnitude of clinical benefit of cancer drugs approved by the US food and drug administration","volume":"110","author":"Tibau","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.lana.2023.100506_bib5","first-page":"120","article-title":"Potential cost implications for all US food and drug administration oncology drug approvals in 2018","volume":"181","author":"Demartino","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lana.2023.100506_bib6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost\u2013benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lana.2023.100506_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2020.113042","article-title":"Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US","volume":"258","author":"Salas-Vega","year":"2020","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.lana.2023.100506_bib8","article-title":"Financial pollution in the US Health care system","volume":"2","author":"Wagner","year":"2021","journal-title":"JAMA Heal Forum"},{"key":"10.1016\/j.lana.2023.100506_bib9","series-title":"Pricing of cancer medicines and its impacts","year":"2018"},{"key":"10.1016\/j.lana.2023.100506_bib10","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.3390\/curroncol29080455","article-title":"Implications of oncology trial design and uncertainties in efficacy-safety data on health technology assessments","volume":"29","author":"Trapani","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.lana.2023.100506_bib11","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMsa1200223","article-title":"Regulatory review of novel therapeutics \u2014 comparison of three regulatory agencies","volume":"366","author":"Downing","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lana.2023.100506_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254585","article-title":"Potential negative impact of reputed regulators decisions on the approval status of new cancer drugs in Latin American countries: a descriptive analysis","volume":"16","author":"Dur\u00e1n","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lana.2023.100506_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jval.2020.11.009","article-title":"International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects","volume":"24","author":"Rand","year":"2021","journal-title":"Value Heal"},{"key":"10.1016\/j.lana.2023.100506_bib14","first-page":"1","article-title":"Availability of biological cancer drugs under research: registration and price in Brazil, Colombia, and Mexico","volume":"30","author":"Mosegui","year":"2020","journal-title":"Physis Rev Sa\u00fade Coletiva"},{"key":"10.1016\/j.lana.2023.100506_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.30968\/rbfhss.2022.131.0769","article-title":"Medicines regulation, pricing and reimbursement in Brazil","volume":"13","author":"Ivama-Brummell","year":"2022","journal-title":"Rev Bras Farm\u00e1cia Hosp e Servi\u00e7os Sa\u00fade"},{"key":"10.1016\/j.lana.2023.100506_bib17","series-title":"Drug Market Regulation Chamber (CMED). Resolution No. 2, dated 5 March 2004. Establishes the criteria for defining prices of new products and new pharmaceutical presentations","year":"2004"},{"key":"10.1016\/j.lana.2023.100506_bib18","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.lana.2023.100506_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/jamainternmed.2021.3505","article-title":"Communication of survival data in US food and drug administration-approved labeling of cancer drugs","volume":"181","author":"Naci","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lana.2023.100506_bib20","series-title":"Comunicado no 15, de 27 de dezembro de 2006, sobre a defini\u00e7\u00e3o do pre\u00e7o inicial de medicamentos novos","year":"2006"},{"key":"10.1016\/j.lana.2023.100506_bib21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US food and drug administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.lana.2023.100506_bib22","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","article-title":"Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.lana.2023.100506_bib23","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/jamainternmed.2021.5983","article-title":"Real-world use of and spending on new oral targeted cancer drugs in the US, 2011-2018","volume":"181","author":"Fu","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.lana.2023.100506_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1470-2045(15)00449-0","article-title":"Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study","volume":"17","author":"Vogler","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lana.2023.100506_bib26","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(19)33177-0","article-title":"Generating comparative evidence on new drugs and devices after approval","volume":"395","author":"Cipriani","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lana.2023.100506_bib27","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1056\/NEJMp2104846","article-title":"\u201cDangling\u201d accelerated approvals in oncology","volume":"384","author":"Beaver","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.lana.2023.100506_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/d41573-019-00068-x","article-title":"Added therapeutic benefit and drug licensing","volume":"18","author":"Eichler","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lana.2023.100506_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00228-016-2174-2","article-title":"Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice","volume":"73","author":"Maignen","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.lana.2023.100506_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40258-021-00670-4","article-title":"Comparison of prices and affordability of cancer medicines in 16 countries in Europe and Latin America","volume":"20","author":"Moye-Holz","year":"2021","journal-title":"Appl Health Econ Health Policy"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X23000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:55:56Z","timestamp":1757404556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X23000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":28,"alternative-id":["S2667193X23000807"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2023.100506","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2023.100506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100506"}}